MedTrace Logo

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

NCT04093167 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2026-03-11

No results posted yet for this study

Summary

The standard or usual treatment for this disease is pembrolizumab given by needle into the veins (IV).

Some cancers shed DNA (circulating tumour DNA or ctDNA) or genes (biomarkers) into the blood, and levels of these biomarkers may be able to tell researchers how people respond to treatment with pembrolizumab before they feel worse, or the cancer is worse on imaging tests. Researchers are studying how levels of these biomarkers can show how cancers are responding to treatment and whether adding chemotherapy to pembrolizumab based on detection of ctDNA can offer better results.

Conditions

Interventions

DRUG

Pembrolizumab

Per current Product Monograph/U.S. Drug Label and/or local guidelines.

Sponsors & Collaborators

  • Cancer Research Institute, New York City

    collaborator OTHER

  • Personal Genome Diagnostics

    collaborator INDUSTRY

  • Mark Foundation for Cancer Research

    collaborator UNKNOWN

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Valsamo Anagnostou · Johns Hopkins University

  • Sara Moore · Ottawa Hospital Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-26
Primary Completion
2026-12-31
Completion
2027-07-30
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04093167 on ClinicalTrials.gov